CELDARA MEDICAL, LLC
- LEBANON, NH 03766-1441
- celdaramedical.com (company website, opens in a new tab)
- Partnership or Limited Liability Partnership
- SAM active
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
- Small Business
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $0
- Awards on record
- 0
- Contract vehicles
- 0
- Verified credentials
- 0
Compliance posture: unverified (SAM.gov baseline only)
CELDARA MEDICAL, LLC has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
About CELDARA MEDICAL, LLC
- Headquarters
- LEBANON, NH 03766-1441
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIMMVKQXZUBMQ7
- CAGE58S17
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
No federal prime awards on record
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 52 awards
- Total awarded
- $49,304,220
- By phase
- SBIR Phase I: 31
- SBIR Phase II: 16
- STTR Phase I: 3
- STTR Phase II: 2
- By agency
- Department of Health and Human Services: 52
- Active projects
- 1 project
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 1 project
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2025: 1
- 2024: 1
- 2023: 5
- 2022: 5
- 2021: 2
- 2020: 5
- 2019: 6
- 2018: 4
- 2017: 5
- 2015: 4
- 2014: 5
- 2013: 1
- 2012: 3
- 2011: 2
- 2010: 2
- 2009: 1
Awards (most recent first)
Development of CM-HZ01 as a non-alpha-IL2 therapeutic for the treatment of metastatic melanoma
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2025 · $1,228,902
Jan 1, 2025 – Dec 31, 2026
- Active
- Ends Dec 2026
Solicitation PA23-230 (2023) · Topic 102
Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2024 · $1,842,880
Sep 1, 2024 – Aug 31, 2026
Solicitation PA22-176 (2022) · Topic 105
Kv2.1-Targeted First in Class Neuroprotective Therapeutic for Acute Ischemic Stroke
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $653,080
Sep 20, 2023 – May 31, 2026
Solicitation PA21-259 (2021) · Topic 105
Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $466,950
Sep 19, 2023 – Aug 31, 2024
Solicitation PA22-176 (2022) · Topic 105
Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2023 · $1,999,260
Sep 8, 2023 – Aug 31, 2025
Solicitation PA21-259 (2021) · Topic 200
Development of CM-IAV1 for Treatment of High-risk Pandemic Influenzas
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2023 · $1,998,010
Jun 12, 2023 – May 30, 2025
Solicitation PA21-259 (2021) · Topic NIAID
A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome
STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2023 · $2,949,803
Mar 1, 2023 – Feb 28, 2026
Solicitation PA21-262 (2021) · Topic NIAID · Research partner: UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $267,818
Sep 22, 2022 – Aug 31, 2023
Solicitation PA21-259 (2021) · Topic 200
Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2022 · $1,482,122
Sep 1, 2022 – Aug 31, 2024
Solicitation PA20-260 (2020) · Topic 102
Development of a broad spectrum antimicrobial to combat chronic lung infection
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $300,590
Aug 10, 2022 – Jul 31, 2023
Solicitation PA21-259 (2021) · Topic NHLBI
CAR T platform to treat solid tumors
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $368,052
Aug 1, 2022 – Jul 31, 2023
Solicitation PA21-259 (2021) · Topic 102
Development of CM-IAV1 for Treatment of High-risk Pandemic Influenzas
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $300,000
Apr 25, 2022 – Mar 31, 2023
Solicitation PA21-259 (2021) · Topic NIAID
Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2021 · $274,085
Sep 8, 2021 – Jul 31, 2022
Solicitation PA20-260 (2020) · Topic 102
A Novel Broad-spectrum Antiviral Agent
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2021 · $590,654
Jan 1, 2021 – Dec 31, 2022
Solicitation PA19-270 (2019) · Topic NIAID · Research partner: UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
Biomarker of IAPP dysfunction in prediabetes and early type 2 diabetes mellitus (T2DM)
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $299,152
Sep 11, 2020 – Aug 31, 2021
Solicitation PA19-272 (2019) · Topic 200
Mitigation of Acute Kidney Injury (AKI) using the polymer prodrug, APP-103TM
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2020 · $1,745,849
Aug 1, 2020 – Jul 31, 2022
Solicitation PA18-574 (2018) · Topic 400
Autonomous RNA-Mediated Anti-Influenza A Virus Therapeutics (AMRed Therapeutics)
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $258,360
Apr 17, 2020 – Mar 31, 2021
Solicitation PA19-270 (2019) · Topic NIAID · Research partner: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Development of CM-SV1, a monoclonal antibody treatment for Sudan Virus
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2020 · $2,922,162
Mar 25, 2020 – Feb 28, 2023
Solicitation PA17-302 (2017) · Topic NIAID
SBIR TOPIC 081: ADJUVANT DEVELOPMENT FOR VACCINES AGAINST INFECTIOUS OR IMMUNE-MEDIATED DISEASES
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $599,977
Solicitation year 2019 · Topic 81
Antimicrobial peptides to combat MDR ESKAPE pathogens
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $298,691
Sep 5, 2019 – Aug 31, 2020
Solicitation PA18-574 (2018) · Topic R
Cellular Immunotherapy for Systemic Sclerosis
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2019 · $1,480,622
Sep 1, 2019 – Aug 31, 2021
Solicitation PA18-574 (2018) · Topic NIAMS
DRIVEN: Accelerating Medical Entrepreneurship in the Northeast
STTR Phase II · Department of Health and Human Services (National Institutes of Health) · 2019 · $3,167,970
Sep 1, 2019 – Aug 31, 2021
Solicitation GM18-001 (2018) · Topic 500 · Research partner: UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
Mitigation of Acute Kidney Injury (AKI) using the polymer prodrug, APP-103TM
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $224,170
May 1, 2019 – Apr 30, 2020
Solicitation PA18-574 (2018) · Topic 400
A novel antibody therapy for Sin Nombre virus infection
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $594,250
Jan 1, 2019 – Dec 31, 2020
Solicitation PA18-574 (2018) · Topic NIAID
Discovery of Parasite-Derived Tolerogenic Adjuvants
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $599,234
Solicitation year 2018 · Topic NIAID
Showing the 25 most recent of 52 awards.
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 541714Research and Development in Biotechnology (except Nanobiotechnology)PrimarySmall business under this code’s size standard
- 325414Biological Product (except Diagnostic) ManufacturingSmall business under this code’s size standard
- 541715Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SAM.gov reports this entity as small under 2 of 3 NAICS codes. Size is determined per code (SBA size standards).
Product & service codes (PSC)
- 6505DRUGS AND BIOLOGICALS
- 6509DRUGS AND BIOLOGICALS, VETERINARY USE
- AN11HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH
- AN12HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH
- AN13HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT
- AN14HEALTH R&D SERVICES; HEALTH CARE SERVICES; R&D ADMINISTRATIVE EXPENSES
- AN15HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPENSES FOR R&D FACILITIES AND MAJOR EQUIPMENT
- AN22HEALTH R&D SERVICES; HEALTH RESEARCH AND TRAINING; APPLIED RESEARCH
- AN23HEALTH R&D SERVICES; HEALTH RESEARCH AND TRAINING; EXPERIMENTAL DEVELOPMENT
- AN24HEALTH R&D SERVICES; HEALTH RESEARCH AND TRAINING; R&D ADMINISTRATIVE EXPENSES
- AN25HEALTH R&D SERVICES; HEALTH RESEARCH AND TRAINING; EXPENSES FOR R&D FACILITIES AND MAJOR EQUIPMENT
PSC names from the Acquisition.gov PSC Manual (opens in a new tab) (April 2025 edition), checked Nov 12, 2026.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with CELDARA MEDICAL, LLC?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.